Anwen Xiong

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Jia Yu, Anwen Xiong, Qiming Wang, Jianhua Chen et autres

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR-activating mutations. In this phase III, randomized, double-blind trial in China, 336 eligible patients …

cn, ph (code pays fourni par la source)

Sequential Chemoradiotherapy Combined with Immunotherapy Versus Sequential Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study with Propensity Score Matching

Qinghua Xu, Xiaoshuai Yuan, Shuyan Meng, G. Gao et autres

cn (code pays fourni par la source)

Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor–Refractory NSCLC

Haoyue Guo, Yuanyuan Wang, Meng Diao, Ruoshuang Han et autres

INTRODUCTION: Acquired resistance to third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) is a major challenge in NSCLC, with approximately 50% of cases lacking precise resistance mechanisms. This study investigates the immunosuppressive tumor microenvironment (TME) driving resistance and develops a novel triple-combination therapy to restore …

cn (code pays fourni par la source)

Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study

Qianyi Wang, Anwen Xiong, Chenyu Mao, Wenxiang Wang et autres

OBJECTIVE: To evaluate the efficacy and safety of the anti-lymphocyte activation gene-3 (LAG-3) antibody IBI110 in combination with sintilimab and chemotherapy in patients with advanced squamous non-small cell lung cancer (sqNSCLC). METHODS: In this multicenter, randomized, open-label, phase II study, 153 patients …

cn (code pays fourni par la source)

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC

Yuanyuan Wang, Haoyue Guo, Ruoshuang Han, Yuhan Wu et autres

PURPOSE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used as the standard-of-care first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, EGFR-TKI resistance has become a major challenge for almost all patients with EGFR-mutated NSCLC. Both …

cn (code pays fourni par la source)

616 Initial safety and efficacy results from a first in human, phase 1/2 study of ASKG915, an anti-PD-1/Pro-IL-15 bifunctional fusion protein, for patients with advanced solid tumors

Jian Zhang, J. Li, Xianli Yin, Jianzhen Shan et autres

Background ASKG915 is a bifunctional fusion protein of PD-1 antibody fused with an IL-15 prodrug. Preclinical studies demonstrated its efficacy in neoplastic models. Here, we present initial safety and efficacy results from a first-in-human, dose escalation and dose expansion of ASKG915 monotherapy …

cn (code pays fourni par la source)

The pathogenesis and therapeutic management of rare pulmonary sarcomatoid carcinoma: a narrative review

Qianyi Wang, Haoyue Guo, Yuanyuan Wang, Taiping He et autres

Background and Objective: Pulmonary sarcomatoid carcinoma (PSC) accounts for approximately 0.5% of non-small cell lung cancer (NSCLC) cases and is thus a rare subtype. Highly aggressive and hard to detect early, PSC responds poorly to surgery, radiotherapy, and chemotherapy. Therefore, this review …

cn (code pays fourni par la source)

Ivonescimab versus pembrolizumab in PD-L1-positive NSCLC – Authors' reply

Anwen Xiong, Jianhua Chen, Lin Wu, Caicun Zhou

cn (code pays fourni par la source)

Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis

Jia Yu, Sha Zhao, Lei Wang, Xinlong Zheng et autres

ABSTRACT This study aimed to investigate the efficacy, safety, and predictors of camrelizumab combined with carboplatin and nab‐paclitaxel as first‐line setting for patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). Camrelizumab plus carboplatin and nab‐paclitaxel were administrated every 3 weeks for four to …

cn (code pays fourni par la source)

Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions.

M. Pérol, Wěi Li, Nathan A. Pennell, Geoffrey Liu et autres

8643 Background: Taletrectinib is a highly potent, next-generation, central nervous system–active, selective ROS1 tyrosine kinase inhibitor (TKI) that was evaluated in 2 pivotal ROS1+ non–small cell lung cancer (NSCLC) phase 2 trials: the regional TRUST-I (NCT04395677) and global TRUST-II (NCT04919811) studies. While …

fr, cn, us, ca, it, es (code pays fourni par la source)

Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST

M. Pérol, Wei Li, Nathan A. Pennell, Geoffrey Liu et autres

PURPOSE: + non-small cell lung cancer. METHODS: TRUST-I and TRUST-II were phase II, single-arm, open-label, nonrandomized, multicenter trials. Efficacy outcomes were pooled from TRUST-I and TRUST-II pivotal cohorts. The safety population comprised all patients treated with once-daily oral taletrectinib 600 mg pooled …

fr, cn, us, ca, jp, it, es (code pays fourni par la source)

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Anwen Xiong, Lei Wang, Jianhua Chen, Lin Wu et autres

cn (code pays fourni par la source)